Abstract
Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as Tumor necrosis factor (TNF), Interleukin-6 (IL-6) and CTLA-4 has become a major focus in the field. Biologic agents are generally more effective than traditional disease-modifying antirheumatic drugs (DMARDs) when combined with MTX. However, not only about 30% of patients respond poorly to treatment but also the parenteral mode of administration and expenses are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy on active RA in clinical trials. Among several JAK inhibitors under clinical trials for RA, tofacitinib (former CP690,550) which is highly specific for JAK3 is a step ahead for use in clinic. Kinase inhibitors are orally available, which is a major advantage over biologic agents, in addition to being less expensive than biologics. This review describes recent advances in JAK inhibitors for the treatment of RA and their possible mechanism of action.
| Original language | English |
|---|---|
| Pages (from-to) | 306-312 |
| Number of pages | 7 |
| Journal | Current Rheumatology Reviews |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2011 Nov |
| Externally published | Yes |
Fingerprint
Keywords
- Janus kinase
- Kinase inhibitor
- Rheumatoid arthritis
- Tofacitinib
ASJC Scopus subject areas
- Rheumatology
Cite this
Janus kinase (JAK) inhibitors in rheumatoid arthritis. / Yamaoka, Kunihiro; Tanaka, Yoshiya.
In: Current Rheumatology Reviews, Vol. 7, No. 4, 11.2011, p. 306-312.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Janus kinase (JAK) inhibitors in rheumatoid arthritis
AU - Yamaoka, Kunihiro
AU - Tanaka, Yoshiya
PY - 2011/11
Y1 - 2011/11
N2 - Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as Tumor necrosis factor (TNF), Interleukin-6 (IL-6) and CTLA-4 has become a major focus in the field. Biologic agents are generally more effective than traditional disease-modifying antirheumatic drugs (DMARDs) when combined with MTX. However, not only about 30% of patients respond poorly to treatment but also the parenteral mode of administration and expenses are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy on active RA in clinical trials. Among several JAK inhibitors under clinical trials for RA, tofacitinib (former CP690,550) which is highly specific for JAK3 is a step ahead for use in clinic. Kinase inhibitors are orally available, which is a major advantage over biologic agents, in addition to being less expensive than biologics. This review describes recent advances in JAK inhibitors for the treatment of RA and their possible mechanism of action.
AB - Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as Tumor necrosis factor (TNF), Interleukin-6 (IL-6) and CTLA-4 has become a major focus in the field. Biologic agents are generally more effective than traditional disease-modifying antirheumatic drugs (DMARDs) when combined with MTX. However, not only about 30% of patients respond poorly to treatment but also the parenteral mode of administration and expenses are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy on active RA in clinical trials. Among several JAK inhibitors under clinical trials for RA, tofacitinib (former CP690,550) which is highly specific for JAK3 is a step ahead for use in clinic. Kinase inhibitors are orally available, which is a major advantage over biologic agents, in addition to being less expensive than biologics. This review describes recent advances in JAK inhibitors for the treatment of RA and their possible mechanism of action.
KW - Janus kinase
KW - Kinase inhibitor
KW - Rheumatoid arthritis
KW - Tofacitinib
UR - http://www.scopus.com/inward/record.url?scp=82255170445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82255170445&partnerID=8YFLogxK
U2 - 10.2174/157339711798221086
DO - 10.2174/157339711798221086
M3 - Article
VL - 7
SP - 306
EP - 312
JO - Current Rheumatology Reviews
JF - Current Rheumatology Reviews
SN - 1573-3971
IS - 4
ER -